MRD对急性髓系白血病预后评价作用的研究进展  

Research Progress on the Prognostic Evaluation of MRD in Acute Myeloid Leukemia --Review

作　　者：刘恒 李子坚[2] LIU Heng;LI Zi-Jian(The First Clinical Medical College of Lanzhou University;Department of Hematology,The First Hospital of Lanzhou University,Lanzhou 730000,Gansu Province,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院血液科,甘肃兰州730000

出　　处：《中国实验血液学杂志》2024年第2期625-629,共5页Journal of Experimental Hematology

基　　金：CDCA5作为白血病预后指标和治疗靶标的研究(2020-ZD-68)。

摘　　要：急性髓系白血病(AML)是异质性极高的一组血液系统恶性肿瘤。虽然相当数量的AML患者经化疗、靶向治疗联合/不联合HSCT而获得长期生存,但是仍有部分患者难以达到缓解或缓解后早期复发,因此,细化风险分层并实现个体化治疗的预后指标具有重要意义。随着AML预后指标研究的日渐深入,预后分层也随之不断改进完善,由依赖MICM分型指标发展到联合治疗后MRD等疾病生物学特征指标的综合评价。本文综述了AML预后指标的发展及MRD对AML预后评价作用的研究进展,以帮助更好地识别不同风险的患者,有利于精准诊治方案的制订和实施。Acute myeloid leukemia(AML)is a highly heterogeneous group of malignant tumors in the blood system.Although many AML patients have achieved survive for a long time through chemotherapy and targeted therapy combined with/without HSCT,but some of them still be difficult to achieve remission or early relapse after remission.Therefore,refining risk stratification and achieving individualized treatment based on prognostic indicators is of great significance.As the research on prognostic indicators of AML deepens increasingly,the prognostic stratification has been continuously improved,from the MICM typing index to the comprehensive evaluation of biological disease characteristics such as MRD.This article reviews the development of prognostic indicators for AML and the research progress of MRD on AML prognosis evaluation to better identify patients with different risks and formulate and implement accurate diagnosis and treatment programs.

关 键 词：急性髓系白血病 微小残留病 进展 

分 类 号：R733.71[医药卫生—肿瘤]